Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Acasti Pharma Inc. V.ACST

Alternate Symbol(s):  ACST

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all which could help to increase treatment compliance and improve patient outcomes.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSXV:ACST)

Fundamentals Snapshot (TSXV:ACST)

Opinion & Analysis (TSXV:ACST)

No current opinion is available.

Bullboard Posts (TSXV:ACST)

GTX-104 positive results

As annouced today:  Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting...
bingostar - May 18, 2022

Acasti Pharma to Present

LAVAL, Qubec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today...
Betteryear2 - April 25, 2022

acasti

Credability at work.This stock has not yet met any significant forcast.Carepre was badly promoted and the real reason it failed has never...
alanmar1 - April 3, 2022

RE:Over 200K on the bid, which is 1% of outstanding shares

Now 131,900 at the bid of $1.86 ... I think this or these buyers are very hungry buyers ... Let the wolves feast and pick up all the low...
flush777 - January 5, 2022

RE:Oppenheimer report on Acasti, outperform, target US $6

ok, the issuance of the report triggered a rush to a high of $2.30 on Dec 22, 2021. I guess that the whole world knows of the report...
flush777 - January 5, 2022

Oppenheimer report on Acasti, outperform, target US $6

Report dated Dec 21, 2021 ... Hum, graph looks great for any potential investor ...
flush777 - January 5, 2022